Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway

• Published in: Pharmaceutical biology 2022-12, Vol.60 (1), p.1520-1532
• Main Authors: Huang, Xi, Yu, Hang, Xie, Cong, Zhou, Yao-Long, Chen, Meng-Meng, Shi, Han-Lin, Tang, Wei-Feng, Dong, Jing-Cheng, Luo, Qing-Li
• Format: Article
• Language: English
• Subjects: Allergic asthma; Asthma; Cytokines; Immunoglobulin E; Inflammation; Interleukin 13; Interleukin 2; Interleukin 4; Interleukin 5; interleukin-33; Lung diseases; mucus secretion; NF-κB protein; Ovalbumin; Respiratory function; Respiratory system; Respiratory tract; Respiratory tract diseases; Signal transduction; suppression of tumorigenicity 2; TOR protein; Traditional Chinese medicine; Tumor necrosis factor-α; γ-Interferon
• ISSN: 1388-0209; 1744-5116
• DOI: 10.1080/13880209.2022.2104327

Asthma is a common respiratory system disease. Louki Zupa decoction (LKZP), a traditional Chinese medicine, presents a promising efficacy against lung diseases. To investigate the pathogenic mechanism of asthma and reveal the intervention mechanism of LKZP. Forty-eight female Balb/c mice were randomly divided into 6 groups: normal control group (NC), ovalbumin (OVA)/saline asthma model group, OVA/LL group, OVA/LM group, OVA/LH group and OVA/DEX group (n = 8 per group). The asthmatic mice were modelled through intraperitoneal injecting and neutralizing OVA. LKZP decoction was administrated by gavage at the challenge stage for seven consecutive days (2.1, 4.2 and 8.4 g/kg/day). We investigated the change in lung function, airway inflammation, mucus secretion and TH-1/TH-2-related cytokines. We further verify the activated status of the IL-33/ST2/NF-κB/GSK3β/mTOR signalling pathway. LKZP was proved to improve asthmatic symptoms, as evidenced by the down-regulated airway resistance by 36%, 58% and 53% (p